Bonds Group

Bond Biosciences is a clinical-stage biopharmaceutical company focused on the development of first-in-class, non-absorbed oral therapeutics that bind excess metal ions locally in the gastrointestinal (GI) tract. The company's technology platform enables the design of high-avidity polymers that selectively sequester dietary or secreted ions—such as iron, potassium, or ammonia—preventing their absorption into the bloodstream. This approach is designed to treat systemic ion-related disorders with a localized, gut-restricted mechanism, minimizing systemic side effects. Its lead candidate, BBI-001, is in Phase 1/2 development for the treatment of iron overload in patients with Hereditary Hemochromatosis, potentially replacing or reducing the burden of lifelong therapeutic phlebotomy. The company leverages technology originally developed at the University of Kansas and is headquartered in the United States.